TY - JOUR T1 - Reanalysis of the Pfizer mRNA BNT162b2 SARS-CoV-2 vaccine data fails to find any increased efficacy following the boost: Implications for vaccination policy and our understanding of the mode of action JF - medRxiv DO - 10.1101/2021.02.23.21252315 SP - 2021.02.23.21252315 AU - Allan Saul AU - Heidi E. Drummer AU - Nick Scott AU - Tim Spelman AU - Brendan S. Crabb AU - Margaret Hellard Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/01/2021.02.23.21252315.abstract N2 - Background In clinical trials two vaccinations with mRNA vaccines have shown high efficacy in preventing COVID-19. However, in the context of a pandemic, the time to generation of protective immunity, the need for and timing of a second vaccination are matters of legitimate debate. This manuscript explores the efficacy and timing of the second dose COVID-19 vaccines, including a reanalysis of data from the Pfizer mRNA BNT162b2 mRNA SARS-CoV-2 vaccine phase 3 study.Methods and findings A non-weighted three-segment, two knot linear regression was fitted to the published cumulative infection incidence from the Pfizer BNT162b2 vaccine Phase III trial using the lspine routine in R. The optimal knot days were estimated through sensitivity analysis and the confidence limits for efficacy estimates were determined by Monte Carlo Simulations. This analysis showed the vaccine was effective from day 11 post first vaccination. The estimated efficacy over the period 11 to 28 days post first vaccination was 0.94 and there was no detectable increase in efficacy following the second vaccination. The efficacy post first vaccination substantially preceded the development of detectable serum neutralizing antibody.Conclusions Strongly protective immunity develops rapidly following a single vaccination and at least in the short period covered by the timetable of the Phase III trial, there was no additional benefit from a second vaccination. This increases options for use of this vaccine, e.g., for ring fence vaccination, for use in travelers and for mass vaccination rollout. It highlights the need for further research into duration of immunity following a single vaccination and for understanding mechanisms of protection.Competing Interest StatementNS and MH provide guidance to the Victorian Government COVID-19 response and receive funding from the Victorian Government for the Optimise Study and COVID-19 modelling work. NS received funding from Johnson & Johnson in Jun-Sep 2020 to provide incidence projections for potential vaccine trial sites. BC serves on the Australian National COVID-19 Health Research Advisory Committee that provides guidance to the Australian Federal Government COVID-19 response. Clinical Trialre-analysis of published data from NCT04368728Funding StatementNo external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB/oversight is required. Re-analysis of published data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesPrimary data is available from publications listed in the paper. Data derived from these publications are listed in the text and in a supplementary fileE11-28, E28-111Vaccine efficacies from day 11 to day 28 and from day 28 to day 111, respectivelys.e.standard errorCIconfidence interval ER -